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Abstract
Background: Although the vast majority of cells in our brains are glia, we are only beginning to understand
programs governing their development, especially within the embryonic hypothalamus. In mice, gliogenesis is a
protracted process that begins during embryonic stages and continues into the early postnatal period, with glial
progenitors first producing oligodendrocyte precursor cells, which then differentiate into pro-oligodendrocytes, pro-
myelinating oligodendrocytes, and finally, mature myelinating oligodendrocytes. The exact timing of the transition
from neurogenesis to gliogenesis and the subsequent differentiation of glial lineages remains unknown for most of
the Central Nervous System (CNS), and is especially true for the hypothalamus.
Methods: Here we used mouse embryonic brain samples to determine the onset of gliogenesis and expansion of
glial populations in the tuberal hypothalamus using glial markers Sox9, Sox10, Olig2, PdgfRα, Aldh1L1, and MBP. We
further employed Ascl1 and Neurog2 mutant mice to probe the influence of these proneural genes on developing
embryonic gliogenic populations.
Results: Using marker analyses for glial precursors, we found that gliogenesis commences just prior to E13.5 in the
tuberal hypothalamus, beginning with the detection of glioblast and oligodendrocyte precursor cell markers in a
restricted domain adjacent to the third ventricle. Sox9+ and Olig2+ glioblasts are also observed in the mantle
region from E13.5 onwards, many of which are Ki67+ proliferating cells, and peaks at E17.5. Using Ascl1 and
Neurog2 mutant mice to investigate the influence of these bHLH transcription factors on the progression of
gliogenesis in the tuberal hypothalamus, we found that the elimination of Ascl1 resulted in an increase in
oligodendrocyte cells throughout the expansive period of oligodendrogenesis.
Conclusion: Our results are the first to define the timing of gliogenesis in the tuberal hypothalamus and indicate
that Ascl1 is required to repress oligodendrocyte differentiation within this brain region.
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Background
The tuberal hypothalamus, consisting of the ventro-
medial hypothalamus (VMH), dorsomedial hypothal-
amus (DMH), and arcuate nucleus (ARC), is a key
regulator of many important biological functions, such
as energy balance, sexual behavior, thermoregulation,
and affective functioning [1–4]. Although most of the re-
search within this brain region is focused on under-
standing neuronal differentiation and function, the glial
cells that interact with hypothalamic neurons also play a
critical role in controlling homeostatic mechanisms, par-
ticularly aspects of feeding regulation [5, 6].
Gliogenesis is the developmental process of generating
the supportive and active signalling central nervous sys-
tem (CNS) glial cells, namely oligodendrocytes and as-
trocytes. Temporally, gliogenesis has been shown to
follow embryonic neurogenesis in the CNS. Indeed, the
differentiation of oligodendrocytes, which are the last
cell type to differentiate in the CNS, has been well de-
fined in the cortex and spinal cord and begins around
embryonic day (E) 12.5, occurring in three consecutive
waves each from its own distinct domain, as has been
extensively reviewed elsewhere [7, 8]. Briefly, oligoden-
drocytes arise from Sox9+ progenitor cells that express
the transcription factor Olig2 within restricted regions
of the ventral neuroepithelium throughout the rostro-
caudal axis. These progenitors further mature and start
to migrate outwards after starting to express Sox10 and
PdgfRα. Once in the mantle region, these glioblasts
begin to actively proliferate and give rise to the many
oligodendrocyte precursor cells (OPCs) that are neces-
sary to adequately populate the mantle region. Tempor-
ally, these OPCs continue to mature and upon reaching
their final maturation, these oligodendrocytes begin to
myelinate axons [9–12]. Within the tuberal hypothal-
amus, neural progenitors that line the third ventricle are
known to give rise to both neurons and glia [13]. Yet,
despite considerable understanding of glial development
in other brain regions, primarily the cortex and spinal
cord, the timing for gliogenesis in the hypothalamus
remains undefined.
Interestingly, genes of the basic helix-loop-helix family
(bHLH), particularly Olig2 and proneural genes Neuro-
genin 2 (Neurog2) and Achaete-scute homolog1 (Ascl1)
also influence gliogenesis [14]. For example, during
neurogenesis Olig2 has well-defined roles in the devel-
opment of motor neurons in the spinal cord [15] and
GABAergic neurons in the cortex [16, 17], while later it
is required for the development of oligodendrocytes
in both brain regions and, to a much lesser extent,
ventrally-located astrocytes as observed in the fore-
brain and spinal cord [15, 18, 19].
In the case of proneural genes, their function during
gliogenesis is more varied. For instance, ectopic expression
of Ascl1 in the cerebellum has been shown to increase the
numbers of interneurons while concomitantly supressing
an astrocytic fate; the loss of Ascl1 exhibits the opposite
phenotype [16], suggesting that Ascl1 restricts the differ-
entiation of a shared progenitor pool into astrocytic line-
ages. Similarly in the cortex, Neurog2 and Ascl1 double
knockout animals show increases in an astrocytic fate at
the expense of neurons [20], while a single Ascl1 knockout
shows defects in populations of early-born Pdgfrα+ OPCs
but not of late born OPCs [21]. Comparatively, in the de-
veloping spinal cord loss of Ascl1 in progenitor cells that
would normally produce neurons leads to a reduction in
neurons and an increased expression of immature glial
markers of both astrocyte and oligodendrocyte origin, but
with no change in the OPC marker, Sox10 [22]. Consist-
ently, Ascl1 overexpression in the spinal cord has been
shown to promote the maturation of OPCs into myelin
forming oligodendrocytes [23]. Compounding the hetero-
geneity of the influence of Ascl1 on glial progenitors, it
was recently shown in the spinal cord that Ascl1 affects
both astrocytes and oligodendrocytes differentially in grey
matter and white matter. In Ascl1 knockouts, an increase
in NFIA+, Olig2+, and Sox10+ glioblasts was observed in
the grey matter, which is opposite to that observed in the
white matter glial progenitor populations during later em-
bryonic stages [24]. Interestingly, both Neurog2 and Ascl1
are expressed within progenitors within the tuberal hypo-
thalamus but their role during hypothalamic gliogenesis
has not yet been defined [25].
In this study we determined the spatiotemporal timing
of gliogenesis in the tuberal hypothalamus by quantify-
ing the timing and location of maturing oligodendrocyte,
and to a lesser extent, astrocytes. We also employed
Ascl1- and Neurog2-null mice to investigate the influ-
ence of these bHLH transcription factors in the progres-
sion of gliogenesis in this brain region. By characterizing
the development of oligodendrocytes in this important
brain region, we will be poised to better understand how
disruption of gliogenesis might contribute to hypothal-
amic disease states, such as obesity.
Methods
Mouse strains and tissue preparation
Timed-pregnant wildtype CD1, Neurog2GFPKI [26, 27]
and Ascl1GFPKI [26–28] were bred to obtain embryonic
tissue samples. For embryonic staging, female mice were
plug checked in the morning and those with a positive
vaginal plug were assigned embryonic day (E) 0.5. For
postnatal staging, the day of birth was assigned as post-
natal day (P) 0. Genotyping was confirmed by embryonic
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Animal protocols were approved by the University of
Calgary Animal Care Committee and follow the
Guidelines of the Canadian Council of Animal Care.
For sample preparation, gravid females were anaesthe-
tized with isoflurane and immediately decapitated.
Embryos were removed and embryonic brains were ex-
tracted for E15.5 and E17.5 time points while whole em-
bryonic heads were taken for E11.5 and E13.5
time points. For mutant samples, which have been out-
crossed onto a CD1 background, CD1 wildtype samples
were used as controls, with the exception of Fig. 7e, h
where heterozygous Ascl1+/GFPKI animals were used as
controls. For 5-Bromo-2′-deoxyuridine (BrdU) samples,
200 μl of 10 μg/μl BrdU was injected intraperitoneally
into the pregnant dam. For neuronal birthdating studies,
BrdU was injected at E11.5, E13.5 and E15.5 into the
pregnant dam and resulting pups were sacrificed at P0.
For proliferation studies, BrdU was injected at E13.5 and
30 min before decapitation of dam. Samples were fixed
overnight with 4% paraformaldehyde in phosphate
buffered saline (PBS), washed in PBS, then treated with
20% sucrose before being embedded in O.C.T. for
cryosectioning.
Immunofluorescence
Brain samples were cryosectioned at 10 μm with a selec-
tion sampling fraction of 1 for every 8 serial sections
within our region of interest. Sections were treated with
primary antibody overnight at 4 °C in 5% normal donkey
or goat serum/PBS with 0.1% Tween-20 or Triton-X 100
followed by the appropriate fluorescently conjugated
secondary antibody. Primary antibodies were as follows:
Mouse anti-NeuN (Millipore; 1:400), Rat anti-BrdU
(Cedar Lane; 1:300), Goat anti-Ki67 (Santa Cruz; 1:300),
Rabbit anti-Ki67 (Abcam; 1:100), Goat anti-Sox9 (R&D
systems; 1:40); Rabbit anti-Olig2 (Millipore; 1:500);
Mouse anti-Olig2 (Millipore; 1:300), Goat anti-PdgfRα
(R&D Systems; 1:150); Rat anti-SF-1 (graciously provided
by Dr Taro Tachibana, Osaka City University JAPAN,
1:800); Rabbit anti-TTF-1 (alternatively Nkx2.1; Santa
Cruz; 1:500), Goat anti-Sox10 (Santa Cruz, 1:500),
Rabbit anti-pHH3 (Millipore; 1:500), Rabbit anti-Cyclin
E (Santa Cruz; 1:200), Rabbit anti-Cyclin B1 (Santa Cruz;
1:200), Mouse anti-Cyclin D2 (ThermoFisher Scientific;
1:200), Rabbit anti-p57kip (Sigma; 1:200), Rabbit anti-
Aldh1L1 (Abcam; 1:500), Rat anti-MBP (Millipore; 1:50),
and Rabbit anti-Cleaved Caspase 3 (Abcam; 1:800). All
appropriate secondary antibodies were Donkey or Goat
anti-IgG and Alexa Fluor conjugated (ThermoFisher
Scientific; 1:200–1:400). All samples were counterstained
with Hoechst nuclear stain (ThermoFisher Scientific;
1:1000).
Quantification and statistical analysis
For cell number quantification, images were taken using
a Ziess Axioplan 2 manual compound microscope with
a Zeiss Axiocam HRc camera. Adobe Photoshop CS6
counting software was used to manually count individual
and co-labeled cells. SF-1 staining-which marks the
ventromedial hypothalamic nuclei-was used to denote
the beginning and end of the tuberal hypothalamus
across adjacent brain sections [29] and Nkx2.1 was used
to verify the hypothalamic sulcus border at the dorsal
edge of the tuberal hypothalamus. Cells were counted
from 3 brain sections (descriptive counts) or 2 brain sec-
tions (mutant counts) in the rostral to mid tuberal hypo-
thalamus for WT and mutant brains, respectively.
Aldh1L1 cell counts were taken from the mid to caudal
tuberal hypothalamus for control and mutant brains.
Embryonic samples from more than one pregnant dam
were used for each experimental group. Statistical differ-
ences between controls and mutants and between age
time points were assessed using an ANOVA statistical
test with Tukey post-hoc analysis or a Student’s t-test
when applicable. Results are displayed as mean±standard
deviation (SD).
Results
Glial progenitors first appear after E13.5 in the tuberal
hypothalamus
Neurogenesis precedes gliogenesis throughout the CNS,
prompting us to first ask when neurogenesis is complete
in the tuberal hypothalamus, thereby providing a guide-
line as to when we would expect the onset of gliogenesis.
Here we used BrdU to birthdate neurons born at various
embryonic time points in the developing tuberal hypo-
thalamus since terminally differentiated neurons become
marked by the incorporation of BrdU during their final
S-phase [30]. These birthdating experiments were per-
formed by injecting BrdU into pregnant dams at E11.5,
E13.5 and E15.5, and harvesting embryonic brains at P0.
To define the rostrocaudal boarder of the tuberal hypo-
thalamus, we immunolabeled adjacent sections with
Steroidogenic factor 1 (SF-1, Nr5a1; Additional file 1:
Figure S1), a definitive marker of the VMH [31–33] and
whose rostrocaudal expression we had already deter-
mined [29]. Co-labeling of BrdU and NeuN, a pan-
neuronal marker, revealed a large population of dual-
labeled BrdU+/NeuN+ neurons (Fig. 1a; yellow cells) in
P0 brains injected with BrdU at E11.5, which was dimin-
ished in P0 brains injected with BrdU at E13.5 and
nearly absent in the P0 brains that were injected with
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BrdU at E15.5. Since the majority of cells at this latest
time point had very little detectable BrdU incorporation,
we postulated that E15.5 represents the end of the
neurogenic window (Fig 1a). These data are consistent
with previous reports [34], and lead us to choose E13.5
as our early time point as to when we might expect
gliogenesis to commence, E15.5 as a period of active
gliogenesis, and E17.5 to represent a period of oligo-
dendrocyte maturation.
Next we asked when glioblasts first appeared in the
tuberal hypothalamus by assaying Sox9 expression, a
transcription factor required to specify a glial identity
but that also labels neurogenic progenitors at the end of
neurogenesis [35, 36]. At E11.5 and E13.5, Sox9 expres-
sion was mainly restricted to the ventricular zone (VZ)
where multipotent neural progenitors are located, labeling
the entire dorsal-ventral and rostral-caudal extent of the
tuberal hypothalamic VZ (Additional file 1: Figure S2A
and Fig. 1b). In contrast, by E15.5 and at E17.5, Sox9 ex-
pression was detected both in the VZ, representing a mix
of neural and glial progenitors, and in the mantle zone
(MZ; Fig. 1b), representing likely glial precursors, as the
loss of ventricular contacts by dividing progenitors is a
hallmark feature of glial precursors [37]. We thus con-
clude that the first glial precursors appear in the tuberal
hypothalamus between E13.5 and E15.5.
Olig2+ cells are restricted to a tight domain along the
third ventricle in the tuberal hypothalamus
To more accurately determine when glioblast differenti-
ation commences in the tuberal hypothalamus, we
examined the expression of Olig2, which marks a subset
of glioblasts and maturing OPCs [15, 18]. At E13.5,
Olig2+ cells lined the dorsoventral extent of the VZ sur-
rounding the third ventricle in the anterior hypothal-
amus (Fig. 2a, left image), a region outside of the SF-1+
tuberal hypothalamic domain. In contrast, within the
rostral area of the tuberal hypothalamus where SF-1 ex-
pression was first detected, Olig2+ cells begin to form a
domain whereby they lined only a distinct portion of the
VZ (Fig. 2a, middle image) that was located near the
hypothalamic sulcus that separates the thalamus from
the hypothalamus (Fig. 2a, b). More caudally within the
SF-1+ tuberal hypothalamic area, Olig2+ cells become
even further restricted to a smaller central domain of
the VZ (Fig. 2a, right image), which also abuts the hypo-
thalamic sulcus. This enrichment of Olig2+ cells in a
central domain was most notable at E13.5, just prior to
the release of glioblasts into the MZ (Fig. 2a), however
some Olig2+ cells lining the ventricle of the tuberal
hypothalamus were also observed starting at E11.5
(Additional file 1: Figure S2). By E15.5, when Olig2+
cells began to disperse away from the ventricle (Fig. 2c),
this Olig2+ cluster was less robust and by E17.5 nearly
unrecognizable (Fig. 2c). Olig2+ glioblasts thus occupy a
restricted domain along the third ventricle within the
early embryonic tuberal hypothalamus.
Olig2+ progenitors along the VZ of the tuberal
hypothalamus are not actively dividing
As progenitor cells lining ventricles are well known to
be mitotically active [38], we next determined whether
Olig2+ cells lining the third ventricle were mitotically
active. To label rapidly proliferating S-phase cells, we
injected BrdU at E13.5 and sacrificed the animals 30 min
later. Interestingly, very few Olig2+/BrdU+ double
Fig. 1 Progression of neurogenesis and gliogenesis in the tuberal hypothalamus of CD1 wildtype mice. a P0 brain sections of BrdU birthdating
studies indicating the neurons, marked by NeuN, that were born at E11.5, E13.5 and E15.5 embryonic time points during neurogenesis in the
tuberal hypothalamus. Yellow arrows indicate examples of NeuN+/BrdU+ co-labeled neurons, third ventricle location is highlighted with a white
dotted line. b Sox9+ glioblasts in the tuberal hypothalamus at E13.5, E15.5 and E17.5. Scale bars equal 200 μm
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labeled cells were observed within the Olig2+ domain
along the tuberal hypothalamic VZ, whereas many
BrdU+ cells were detected in the VZ directly dorsal
and ventral to the Olig2+ enriched domain (Fig. 2d).
In addition, Olig2+ cells that had migrated into the
MZ were BrdU+, consistent with a proliferative glio-
blast fate (Fig. 2d).
To further test whether Olig2+ cells in the gliogenic
domain were mitotically active, we co-labeled sections
with Olig2 and the cell proliferation marker Ki67
(Fig. 2e). At E13.5, many Ki67+ cells were observed in
the VZ ventral to the Olig2+ domain (Fig. 2e, white
arrow), as was observed with BrdU+ immunostaining
(Fig. 2d). Interestingly, the Ki67+ cells that were present
Fig. 2 Olig2+ cells appear in a domain region along the 3rd ventricle in the tuberal hypothalamus. a Olig2+ cells located at the third ventricle
(3 V) congregate in a domain in the tuberal area of the hypothalamus at the dorsal edge near the hypothalamic sulcus (dotted white line) at
E13.5. Insets depict the Olig2 staining with the domain area indicated with arrows. b Illustration of coronal plane of nuclei of the tuberal
hypothalamus to depict the hypothalamic sulcus dividing the thalamus (Th) from the hypothalamus (Hy). c Olig2+ cells at E15.5 and E17.5 with
the Olig2+ domain area highlighted in the magnified image. White dotted line outlines the third ventricle. d BrdU and Olig2 co-immunostaining
at E13.5 with areas dorsal to domain, the domain, and ventral to domain highlighted to outline differences in proliferative ability. e Ki67 and Olig2
co-immunostaining at E13.5 and E15.5. White arrow highlights pseudostratified proliferating cells ventral to domain, green arrow highlights a Ki67
+ cell in domain area, yellow arrows indicate Ki67+/Olig2+ cells at the VZ and MZ. Scale bars equal 100 μm
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within the restricted domain at E13.5 were directly adja-
cent to the ventricle wall and not across the ventricular
zone (Fig. 2e, green arrow) and did not co-label with
Olig2 (Fig. 2e, merge), further suggesting that Olig2+
cells within this VZ domain are not actively dividing at
E13.5. Similarly, at E15.5, few Olig2+/Ki67+ cells were
detected in the VZ, with the majority appearing in
the MZ (Fig. 2e, yellow arrows). To further explore
the cell cycle activity of Olig2+ cells within this do-
main, we co-labeled the E13.5 tuberal hypothalamus
with Olig2 and the cell cycle markers phospho-
histone H3 (pHH3), Cyclin E, Cyclin B1, and Cyclin
D2 (Fig. 3a-d). We found no Olig2+/pHH3+ double-
positive cells (Fig. 3a), and very few Olig2+/CyclinE+,
Olig2+/CyclinB1+, and Olig2+/CyclinD2+ cells (Fig. 3b-d,
white arrows). However, co-labeling with Olig2 and the
cell cycle exit marker p57kip [39] showed numerous
double-positive cells (Fig. 3e, white arrows), consistent
with our earlier findings that the majority of Olig2+ cells
within the VZ are not actively dividing at E13.5. Taken to-
gether, these data suggest that Olig2 may have a cell cycle-
restricted expression profile in the E13.5 hypothalamic
VZ, largely being excluded from adjacent rapidly dividing
progenitors.
Changes in glial progenitor and precursor cell
populations in the tuberal hypothalamus across
development
To start to examine the differentiation of OPCs within
the tuberal hypothalamus, we co-immunolabeled em-
bryonic brain slices with Sox9 and Olig2. We first fo-
cused our analyses on cells in the VZ, examining the
Olig2-enriched domain near the hypothalamic sulcus
(Additional file 1: Figure S2A and Fig. 4a, VZ) and
quantifying the Sox9+/Olig2- and Sox9+/Olig2+ cells.
The number of Sox9+/Olig2- progenitor cells in the
tuberal hypothalamic VZ did not significantly change
across development (Fig. 4b): 773±256 cells at E13.5,
1069±211 cells at E15.5, and 940±186 cells at E17.5.
Furthermore, the relative proportion of the Sox9+/Olig2-
population along the VZ also did not change significantly
over time: 94%±1% at E13.5, 94%±3% at E15.5, and
95%±2% at E17.5 (Fig. 4d). Similarly, the number of
Sox9+/Olig2+ progenitor cells in the VZ, which were
lower in number and likely glioblasts on their way to
committing to an OPC fate, did not change signifi-
cantly across embryonic time points (Fig. 4b): 48±5
cells at E13.5, 75±40 cells at E15.5, and 54±24 cells
at E17.5. And consistently, the relative proportion of
Sox9+/Olig2+ in the VZ also did not fluctuate across
development: 6%±1% at E13.5, 6%±1% at E15.5 and
5%±2% at E17.5 (Fig. 4d). Combined, at the VZ nei-
ther Sox9+/Olig2- nor Sox9+/Olig2+ total cell counts
or relative proportions were significantly different
across time points (Fig. 4b, d). We did not detect any
Sox9-/Olig2+ cells at the ventricle at any time point
starting at E11.5, which is when Sox9 is just begin-
ning to be expressed in the tuberal hypothalamus
(Additional file 1: Figure S2A and data not shown).
The tuberal hypothalamic VZ thus has a stable pool
of progenitors expressing glial markers at mid-to-late
embryonic time points.
Given that glial precursors migrate away from the VZ
and into the MZ where they proliferate and mature, we
next examined the number of progenitors expressing
Sox9 and/or Olig2 in the MZ, observing all three pos-
sible populations of glioblasts, namely Sox9+/Olig2-,
Sox9+/Olig2+, Sox9-/Olig2+ (Fig. 4c, e). We first exam-
ined Sox9+/Olig2+ cells, considered to be early-stage
glioblasts and OPCs, and found a significant and dra-
matic increase in number of these cells from E13.5 to
E15.5 and a further increase at E17.5: 76±43 cells at
E13.5, 826±134 cells at E15.5, and 1159±188 cells at
E17.5 (Fig. 4c). Moreover, we also quantified the relative
proportion of the Sox9+/Olig2+ population within the
total Sox9+ and Olig2+ glioblast populations in the
MZ and found Sox9+/Olig2+ population likewise in-
creased from E13.5 to E15.5 and then remained con-
stant to E17.5: 24%±14% at E13.5, 72%±6% at E15.5,
and 58%±6% at E17.5 (Fig. 4e). We next examined
Sox9+/Olig2- cells in the MZ and found this popula-
tion to be relative low and maintained from E13.5 to
E15.5 with a significant increase at E17.5: 342±123
cells at E13.5, 206±cells at E15.5, and 711±138 cells at
E17.5 (Fig. 4c). This was in contrast to the relative propor-
tion of Sox9+/Olig2- glioblasts within the total Sox9+ and
Olig2+ populations, which decreased significantly from
E13.5 to E15.5 but remained constant to E17.5:
72%±18% at E13.5, 18%±4% at E15.5, and 36%±8% at
E17.5 (Fig. 4e). Finally, we quantified the population
of Sox9-/Olig2+ cells, which are likely maturing OPCs
(see next section). Unlike in the VZ where no Sox9-/
Olig2+ cells were detected from E13.5 to E17.5,
within the MZ we identified a distinct population that
significantly increased from E13.5 to E15.5 and
remained constant thereafter to E17.5: 17±14 cells at
E13.5, 111±32 cells at E15.5, and 138±44 cells at E17.5
(Fig. 4c). In contrast, the relative proportion of Sox9-/
Olig2+ glioblasts remained constant across E13.5, E15.5
and E17.5: 4%±5% at E13.5, 10%±3% at E15.5, and 7%±2%
at E17.5 (Fig. 4e). Taken together, these data demonstrate
a major expansion in the MZ from E13.5 to E15.5 of the
Sox9+/Olig2+ population, thought to be OPCs, as well as
a pool of Sox9-/Olig2+ cells that may correspond to dif-
ferentiating OPCs. We also observe a second wave of
later expansion of the Sox9+/Olig2- population,
thought to be early-stage glioblasts and/or astrocyte
precursors between E15.5 and E17.5.
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Oligodendrocyte progenitor and precursor cell
populations in the tuberal hypothalamus
Although the majority of Olig2+ cells go on to be-
come OPCs, a portion of these cells can give rise to
astrocytes [15, 19], so next we examined the popula-
tion of Olig2+ glioblasts committed to becoming
OPCs across development. We employed the OPC
marker PdgfRα, and quantified the number of Olig2+
cells that were either PdgfRα- or PdgfRα+. At E11.5
we did not detect PdgfRα + cells in the developing
hypothalamus (Additional file 1: Figure S2B), consist-
ent with oligodendrogenesis occurring after neurogen-
esis and just prior to E13.5. Moreover, from E13.5 to
E17.5 no PdgfRα + cells were identified within the VZ
(Fig. 5a, VZ) and all Olig2+/PdgfRα+ cells were local-
ized in the MZ, consistent with their expression in
differentiating OPCs and oligodendrocytes (Fig. 5a).
Although PdgfRα labels the cell body and processes
of OPCs and Olig2 is an OPC nuclear marker, dual-
labeling demonstrated quantifiable overlapping expres-
sion in Olig2+/PdgfRα+ cells (Fig. 5a, yellow arrows)
that were distinguishable from Olig2+/PdgfRα- cells
(Fig. 5a, red arrows). Quantification of Olig2+/PdgfRα-
cells, the majority of which will become committed OPCs
at these later embryonic time points [15], significantly in-
creased from E13.5 to E15.5 and remained relatively con-
stant at E17.5, consistent with our previous findings in
Fig. 4: 122±23 cells at E13.5, 641±189 cells at E15.5, and
699±301 cells at E17.5 (Fig. 5b). In contrast, the popula-
tion of Olig2+/PdgfRα+ cells, which are considered com-
mitted to an OPC fate and undergoing differentiation,
significantly increased from E13.5 to E15.5 and continued
to increase at E17.5: 44±12 cells at E13.5, 479±140 cells at
E15.5, and 751±158 cells at E17.5 (Fig. 5b). The relative
proportion of Olig2+/PdgfRα+ cells in the total Olig2+
population significantly increased from E13.5 to E15.5 but
remained relatively constant thereafter to E17.5, demon-
strating that the committed OPC population is about half
of the total Olig2+ cell population at E15.5 and onwards:
27%±5% at E13.5, 43%±7% at E15.5, and 54%±8% at E17.5
(Fig. 5c). Combined, these data reveal a significant expan-
sion of both Olig2+ glioblasts and Olig2+/PdgfRα+ differ-
entiating OPCs/oligodendrocytes from E13.5 to E15.5,
Fig. 3 Olig2+ progenitors along the ventricular zone of the tuberal
hypothalamus are not actively dividing. a Olig2+ cells located near
the third ventricle (3 V) congregate in a domain in the tuberal area
of the E13.5 hypothalamus that does not co-label with PPH3. b-d
Olig2+ cells in the E13.5 tuberal hypothalamus show minimal co-
labeling with the active cell cycle markers b Cyclin E, c Cyclin B1,
and d Cyclin D2. e Olig2 and the cell cycle exit marker p57kip show
strong co-labeling in the E13.5 tuberal hypothalamus. White arrows
highlight cells which co-labeled, while the white dotted line outlines
the third ventricle. Scale bars equal 100 μm
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with maturing cells increasing further from E15.5 to
E17.5.
Maturing oligodendrocyte and astrocyte populations in
the developing tuberal hypothalamus
As previously mentioned, the majority of Olig2+ cells go
on to become OPCs, however a portion of these cells
can give rise to astrocytes [15, 19]. Therefore, we next
examined astrocyte development in the tuberal hypo-
thalamus using Aldehyde dehydrogenase 1 (Aldh1L1)
[40], one of the few astrocyte markers expressed embry-
onically. We compared Aldh1L1 expression with that of
Sox10, which definitely labels maturing OPCs given its
role as a key determinant in terminal oligodendrocyte
differentiation, survival, and migration [11, 41]. Since no
Aldh1L1+ cells were identified prior to E15.5 (data not
Fig. 4 Glial progenitor cell populations in the developing embryonic tuberal hypothalamus at E13.5, E15.5 and E17.5. a Representative images of
glioblast cells immunolabled with antibodies to Sox9 and Olig2 in the tuberal hypothalamic area of wildtype CD1 embryonic brains with boxed
areas magnified for the ventricular zone (VZ; lateral area highlighted with bracket) and mantle zone (MZ). Insets show co-labeling of cells. 3rd
ventricle outlined with dotted line. Glioblast cell counts of glioblast subpopulations that are (b) lining the ventricle in the VZ and c in the MZ.
Proportion of glioblast subpopulations within the total glioblast population (d) lining the ventricle in the VZ and e in the MZ. Bar graphs represent
mean ± SD (n = 4–5 embryos per group; 3 brain sections per embryo). Statistics; *P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001. ANOVA with Tukey
Post-Hoc. Scale bars equal 100 μm
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shown), we co-labeled E15.5 to P8 hypothalamic sections
with Aldh1L1 and Sox10 and only singly positive
Aldh1L1+ cells (Fig. 6a, green arrows) or Sox10+ cells
(Fig. 6a, red arrows) were identified, consistent with
Sox10 being expressed specifically in oligodendrocyte
lineages. Despite Aldh1L1+ astrocytes being detected as
early as E15.5 and E17.5 (Fig. 6a), we only began to ob-
serve astrocyte branching and maturation at P0, which
increased significantly from P4 to P8 (Fig. 6a). We also
observed an increase in the overall number of astrocytes
expressing Aldh1L1 from E15.5 to P8 (Fig. 6a), suggest-
ing that astrocytogenesis is occurring alongside, al-
though slightly delayed from, oligodendrogenesis. We
next examined the population of Olig2+ OPCs that
expressed the maturing oligodendrocyte marker Myelin
basic protein (MBP), which labels both premyelinating
and myelinating oligodendrocytes [40]. Across develop-
ment in the tuberal hypothalamus, we were able to de-
tect MBP as early as E15.5 and E17.5 (Fig. 6b, white
arrows); however, we only observed oligodendrocyte
branching from P0 to P8 (Fig. 6b, white arrows). We also
observed an increase in the number of maturing oligo-
dendrocytes expressing MBP from E15.5 to P8 (Fig. 6b,
white arrows), and at all time points the MBP+ cells also
co-labeled with Olig2 (Fig. 6b inset, white arrows).
Together, these data demonstrate that Olig2+ cells
can go on to become mature oligodendrocytes that
myelinate their axons. Furthermore, although a small
population of Olig2+ cells can give rise to astrocytes
that co-label with Aldh1L1 (see next section), Sox10
Fig. 5 Olig2+ oligodendrocyte progenitor cell populations in the developing embryonic tuberal hypothalamus at E13.5, E15.5 and E17.5. a
Representative images immunolabled with antibodies to PdgfRα and Olig2 in the tuberal hypothalamic area of wildtype CD1 embryonic brains,
with boxed areas magnified for the ventricular zone (VZ; area highlighted with bracket) and mantle zone (MZ). Red arrows indicate examples of
Olig2+/PdgfRα- cells, green arrows indicate examples of Olig2+/PdgfRα + cells. Third ventricle outlined with dotted line. b Cell counts of Olig2+
and PdgfRα + (OPCs) or PdgfRα- (glioblasts) populations in the MZ. c Proportion of PdgfRα + co-labeled and PdgfRα- cell populations within the
total Olig2+ population in the MZ. Bar graphs represent mean ± SD (n = 4–5 embryos per group; 3 brain sections per embryo). Statistics; *P < 0.01,
**P < 0.001, ***P < 0.0001, ****P < 0.0001. ANOVA with Tukey Post-Hoc. Scale bars equal 100 μm
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specifically marks the oligodendrocyte lineage and can
thus be used to distinguish Olig2+ glioblasts that will
become oligodendrocytes (e.g., Olig2+/Sox10+) away
from Olig2+ glioblasts that will become astrocytes
(e.g., Olig2+/Sox10-).
Altered glial progenitor and precursor cell populations in
Ascl1 and Neurog2 mutant embryos
We next investigated whether Neurog2 and/or Ascl1 were
required for gliogenesis in the developing embryonic tub-
eral hypothalamus by using the Neurog2GFPKI/GFPKI and
Fig. 6 Maturing oligodendrocyte and astrocyte populations in the developing tuberal hypothalamus. a Representative images of astrocytes in the
E15.5, E17.5, P0, P4 and P8 tuberal hypothalamic area of wildtype CD1 embryonic brains immunolabled with antibodies to Aldh1L1 and Sox10,
with insets showing higher magnification to confirm there is no co-labeling of Aldh1L1+ astrocytes and Sox10+ cells. b Representative images of
premyelinating and myelinating oligodendrocytes in the E15.5, E17.5, P0, P4 and P8 tuberal hypothalamic area of wildtype CD1 embryonic brains
immunolabled with antibodies to Olig2 and MBP, with insets showing higher magnification to confirm there is co-labeling of Olig2+ cells with
MBP. 3rd ventricle outlined with dotted line. Scale bars equal 250 μm
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Ascl1GFPKI/GFPKI mutant mice whereby GFP replaces the
coding regions of Neurog2 and Ascl1, respectively, thereby
creating null alleles [26–28]. The proneural gene Ascl1
was a strong candidate for playing a role during gliogen-
esis given its broad expression within progenitors across
the VZ during embryonic tuberal hypothalamic develop-
ment (Additional file 1: Figure S3; E12.5 and E14.5), and
overlapping expression with the glioblast and OPC
markers Sox9 (Fig. 1b) and Olig2 (Fig. 2). Since the major
expansion of the OPC population is observed from E15.5
to E17.5 in the developing tuberal hypothalamus, we
restricted our studies to this time period. First, we quanti-
fied whether there was a change in Sox9+ glioblasts in the
MZ of mutant hypothalami (Fig. 7a, b). We found that the
number of Sox9+ cells within the MZ was not significantly
different at E15.5 between Neurog2GFPKI/GFPKI mutants
(548±116 cells), Ascl1GFPKI/GFPKI mutants (451±108;
Fig. 7b) and wild-type controls (580±36 cells). In contrast,
at E17.5, an approximately 1.5-fold significant decrease in
Sox9+ cells was detected in both the Neurog2GFPKI/GFPKI
mutants (980±187 cells) and the Ascl1GFPKI/GFPKI mutants
(859±83 cells) relative to wild-type controls (1365±17;
Fig. 7 Mid- to late- embryonic Sox9+, Olig2+, Sox10+ glial populations in the tuberal hypothalamus of Control, Neurog2 GFPKI/GFPKI and Ascl1 GFPKI/GFPKI
mutant embryo brains. Example images of (a) Sox9+, c Olig2+ glial precursors at E15.5 and E17.5. Total number of (b) Sox9+ and d Olig2+ glioblasts
counted in the mantle region in control, Neurog2 GFPKI/GFPKI and Ascl1 GFPKI/GFPKI embryo brains. e Olig2/Sox10, Olig2/Aldh1L1 and cleaved Caspase3/
GFP immunolabeled E17.5 control and Ascl1 GFPKI/GFPKI mutant embryo brains. Total number of (f) Sox10+ OPCs and g Aldh1L1+ astrocytes counted in
control and Ascl1 GFPKI/GFPKI embryo brains. h Sox10 and Sox10/Olig2 immunolabeled E17.5 control and Ascl1 GFPKI/GFPKI mutant embryo brains. 3 V
outlined with solid white line, hypothalamic sulcus indicated with dotted white line. Bar graphs represent mean ± SD (n = 3 embryos per group; 2 brain
sections per embryo). Statistics: *P < 0.01, **P < 0.001, ***P < 0.0001. ANOVA with Tukey Post-Hoc or Student’s t-test
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Fig. 7b). Moreover, we did not observe any changes in
apoptosis in Ascl1GFPKI/GFPKI mutants by staining for
cleaved Caspase3 (Fig. 7e).
To resolve whether the decrease in Sox9+ cells in the
developing tuberal hypothalamus in Neurog2GFPKI/GFPKI
and Ascl1GFPKI/GFPKI mutants affected oligodendrocyte
development, we quantified changes in Olig2, a general
marker for glioblasts and OPCs, in the MZ (Fig. 7c, d).
In the MZ there was an almost 2-fold increase in Olig2+
cells in Ascl1GFPKI/GFPKI mutants at E15.5 (197±24 cells)
that was also observed at E17.5 (349±60 cells; Fig. 7d),
relative to controls at E15.5 (102±19 cells) and E17.5
(212±47 cells). In contrast, no difference was observed
in Olig2+ cells in Neurog2GFPKI/GFPKI mutants relative to
controls at E15.5 (93±4 cells) and E17.5 (178±14;
Fig. 7d).
Given that a percentage of Olig2+ cells can become
astrocytes, we asked if the increase in the Olig2+ popu-
lation in Ascl1GFPKI/GFPKI mutants was giving rise to an
oligodendrocyte or astrocyte lineage. To do so, we per-
formed immunohistochemistry with Sox10 (Fig. 7e, f )
and showed a statistical increase in Sox10+ cells at both
E15.5 (120±6 cells) and E17.5 (212±34 cells) in the
Ascl1 GFPKI/GFPKI mutant relative to controls at E15.5
(98±9 cells) and at E17.5 (119±6 cells; Fig. 7f). Although
an increase in Sox10+ cells in the Ascl1GFPKI/GFPKI mutant
(Fig. 7f) suggested an increase in the oligodendrocyte
lineage, we also examined astrocytes in Ascl1GFPKI/GFPKI
mutants using Aldh1L1 to mark astrocytes. Co-labeling
with Olig2 and Aldh1L1 demonstrated a decrease in the
Aldh1L1+ astrocyte population in Ascl1GFPKI/GFPKI mu-
tants (145±12 cells) as compared to controls (203±10 cells;
Fig. 7g). The decrease in astrocytes was found in the MZ
just adjacent to the VZ where Olig2+ glioblasts are migrat-
ing outward (Fig. 7e, data not shown), thereby supporting
a role for Ascl1 in directing oligodendrocyte versus astro-
cyte fates. It is interesting to note that these changes also
coincided with the appearance of Sox10+ cells in the VZ
in Ascl1GFPKI/GFPKI mutants (Fig. 7h, arrows), which were
also found to be Olig2+ (Fig. 7h). Together, these data
suggest that Ascl1 but not Neurog2 plays a key role in late
embryonic oligodendrogenesis in the developing tuberal
hypothalamus.
Discussion
Spatiotemporal progression of gliogenesis in the
embryonic tuberal hypothalamus
Here we show the progression of gliogenic expansion in
the embryonic tuberal hypothalamus. We found that
both Sox9+ and Olig2+ glial progenitors form along the
third ventricle and migrate out into the MZ starting
around E13.5, a time point consistent with post-neuro-
genesis. Sox9+/Olig2+ populations, which are likely early-
stage OPCs, expand their population substantially from
E13.5 to E15.5 with another, smaller, expansion onwards
to E17.5. This expansion is further demonstrated by the
increase in the committed OPC population, Olig2
+/PdgfRα+, from E13.5 to E15.5 and continuing to
E17.5. There is also an Olig2+/PdgfRα- glioblast
population that mirrors this growth from E13.5 to
E15.5, which is perhaps a committed astrocytic lineage.
Combined, we propose that the major expansion of oligo-
dendrocyte progenitors and precursors occurs from E13.5
to E15.5 when the first gliogenic wave in the tuberal hypo-
thalamus produces OPCs (Fig. 8).
We report that Olig2+ cells are restricted to a dorsal
domain adjacent to the third ventricle near the hypothal-
amic sulcus of the tuberal hypothalamus, and propose
that OPCs are formed and migrate out from this domain
to establish the MZ glioblasts, which then proliferate to
generate the expansion of oligodendroctyes. Previous
studies have described similar OPC-producing domains
in other CNS regions, as nicely reviewed by Nicolay et
al. [7]. Moreover, this Olig2+ domain demonstrates a re-
duced proliferative capacity at E13.5 in comparison to
the surrounding ventricle progenitors that appear as a
pseudo-stratified layer of Ki67+ and BrdU+ cells likely in
various stages of an active cell cycle due to the appear-
ance of interkinetic nuclear migration [42]. Interestingly,
we did observe a small population of Ki67+ cells within
the Olig2+ domain but they were largely Olig2- in ex-
pression and were tightly localized to the ventricular
wall and did not assume a pseudo-stratified organization.
Here we propose two possible populations of progeni-
tor cells might co-exist within this Olig2+ domain re-
gion, which may have distinctive purposes. Firstly, the
Ki67+/Olig2- progenitor cells directly adjacent to the
ventricle (Fig. 2e) may be in the process of slowing
their cell cycle, inferred by their lack of BrdU accu-
mulation but positive expression of Ki67, and ultim-
ately becoming an alternative neural progenitor type.
In fact, it was recently discovered that adult stem
cells are derived from a subset of the rapidly dividing
neural progenitor pool of cells that have slowed their
cell cycle starting between E13.5 and E15.5 in order
to elongate their cycling potential into adulthood [43].
Coincidentally, overlapping this region of the Olig2+
domain in the tuberal hypothalamic VZ are also pro-
genitors that later generate α-tanycytes, which are
known to have adult stem cell properties [44, 45],
raising the exciting notion that these Ki67+/Olig2-
progenitor cells are being reserved for tanycytic adult
neurogenesis.
Secondly, we also propose that the Ki67-/Olig2+ pro-
genitor population at the VZ are slowing their cell cycle
to become specified as glioblasts, and have paused their
mitotic activity in anticipation of movement as they pre-
pare to exit the VZ. Consistent with this idea, we
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observe accumulation of the cell cycle arrest marker,
p57kip, in cells at the outer edge of the VZ that co-label
with Olig2 (Fig. 3e). This notion would be consistent
with our findings here that Olig2+ cells expand signifi-
cantly out in the MZ after E13.5 and acquire a highly
proliferative state in the mantle. Future studies are
needed to fully understand the proliferative capacity of
cells within this Olig2+ domain, although here we dem-
onstrate that at least two distinct populations reside
within this dorsal VZ domain.
Ascl1 influences gliogenesis in the tuberal hypothalamus
Here we uncovered a unique role for Ascl1 in gliogen-
esis in the tuberal hypothalamus. Both Neurog2- and
Ascl1-null mutants showed a marked reduction in E17.5
Sox9+ cells, although only the Ascl1 single mutant
showed an increase in the Olig2+ and Sox10+ cells at
both at E15.5 and at E17.5 and a decrease in astrocytes
at E17.5, suggesting that oligodendrocyte populations
are increased in the Ascl1 mutant. Since Sox9 is co-
expressed with Olig2 in early OPC populations, this in-
crease in Olig2+ and Sox10+ cells and concomitant de-
crease in the Sox9+ is likely due to a precipitous
increase in OPC maturation in the Ascl1 mutant back-
ground. These changes also coincide with the appear-
ance of Sox10+ cells in the VZ in Ascl1GFPKI/GFPKI
mutants, which were also found to be Olig2+. This sug-
gests that Ascl1 is required to repress precocious OPC
development and oligodendrocyte lineage commitment
of Olig2+ cells lining the ventricle [46–48]. This is fur-
ther supported by the overlap of Ascl1 and Olig2 expres-
sion embryonically in progenitors lining the ventricle.
However, it is important to note that given immature
glia cells divide during their migratory routes, and the
number of divisions determine the number of mature
glia cells, it is also possible that in the absence of Ascl1
astrocytes do not divide to the same extent. Interest-
ingly, these findings in the tuberal hypothalamus are in
direct contrast to those in the cerebellum whereby the
Ascl1 loss-of-function mutants were shown to have a re-
duction in Olig2+ cells and an increase in Sox9+ cells at
E18.5 [16]. Furthermore, a study by Parras et al. using
Ascl1-null mice in the telencephalon demonstrate a de-
crease in PdgfRα+ OPCs during early gliogenesis at
E13.5 that later resolved by E17.5. The OPC population
that was restored late embryonically in their study was
suggested to be due to either an increase in the rate of
proliferation of OPCs or, more likely, an increase in spe-
cification of OPCs from uncommitted progenitors that
reflect a compensatory mechanism for OPC specification
in the absence of Ascl1 [21]. Here we only examined the
mid- (E15.5) to late- (E17.5) stages of embryonic glio-
genesis, and thus, it is possible we missed an initial de-
crease in OPCs earlier (e.g., E13.5), making it possible
that we misinterpreted what was ultimately simply over-
compensation at later stages. However, given that we
show very few PdgfRα OPCs in the developing tuberal
hypothalamus at E13.5, we believe it unlikely that we
missed an OPC phenotype earlier than E15.5. Moreover,
in agreement with our findings here, reports in the
spinal cord also using an Ascl1 knockout show an in-
crease in Olig2+ cells at E17.5, which the authors attri-
bute to aberrant proliferation as Ki67 and BrdU were
also increased [22], and are further supported by a more
recent report in the spinal cord showing an increase in
Olig2+ and Sox10+ cells at E18.5 in grey matter oligo-
dendrocytes [24]. Taken together, our data are consistent
with a role for Ascl1 in oligodendrogenesis, and suggests
that whether Ascl1 is required or represses an OPC fate
might be CNS region-specific.
Mechanistically, we propose that with Ascl1 elimi-
nated, the competency of progenitor cells to maintain a
proliferative state may be reduced since oscillatory Ascl1
cannot cross-repress the other bHLH factors that are re-
quired to maintain a true progenitor state. Indeed, Ascl1
and Neurog2 are both key components of a progenitor
transcription factor oscillatory process whereby progeni-
tors continue to divide instead of exiting the cell cycle
Fig. 8 Progression of timing of neurogenesis, oligodendrogenesis and astrocytogenesis in the embryonic tuberal hypothalamus. Following a first
wave of neurogenesis which ends around E14.5, gliogenesis begins with a second wave producing oligodendrocyte progenitors and OPCs with a
peak in population production around E15.5. Subsequently a third wave of astrocytogenesis produces astrocyte precursor cells between E15.5
and E17.5
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[46] because key transcription factors are expressed for
short periods to cross-repress other transcription factors
in an oscillatory manner. A lineage becomes committed
once a transcription factor stops oscillating and experi-
ences sustained expression [47]. Specifically, when con-
sidering the oscillatory activity of Hes1, Ascl1 and Olig2
in neural progenitor cells, Ascl1 oscillations are required
to maintain a proliferating neural progenitor state, while
sustained Ascl1 expression promotes a neuronal fate.
Alternatively, a decrease in expression of Ascl1 with a
sustained expression of Olig2 or Hes1 promotes an
oligodendrocyte and astrocyte fate, respectively [47, 48].
Thus, in the tuberal hypothalamus, we postulate that the
elimination of Ascl1 in Olig2+ progenitor cells restricts
the neuronal fate potential of these cycling cells, thereby
inducing these progenitors to initiate precocious OPC
development.
Conclusions
In summary, this study provides insight into the spatio-
temporal timing of gliogenesis in the tuberal hypothal-
amus revealing that peak production of developing
oligodendrocytes occurs between E15.5 and E17.5. We
also show a role for Ascl1 in this region that is more
consistent with Ascl1 requirements in the developing
spinal cord than in the cortex and cerebellum.
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